Abstract

Immune system cells express a number of receptors that bind to sugar ligands. This binding initiates the activation of T-cell lymphocytes and natural killer cells. Dr J. Kenneth Hoober, Dr Laura L. Eggink and the team at Susavion have designed peptides that bind to different receptors on immune cells. The peptides effectively extend the lives of mice with glioblastoma and ovarian cancer, and prevent the replication of viruses in the presence of non-neutralising antibodies. The mechanism of action of their peptides could inspire the development of effective treatments for Covid-19 and other viral infections.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.